GlassScriptPhysician profile
Jaideep U Hingorani
NPI 1003023581
$1,061.65
in general payments reported to CMS, 2019-2025
16 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.33 · 2021: $204 · 2023: $145 · 2024: $53.09 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.04 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.99 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $152.73 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $92.43 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $54.54 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $50.12 | 2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.59 | 2023-2025 | Jardiance |
| Amgen INC. | $46.38 | 2021-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $45.21 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $45.14 | 2025 | Ibsrela |
| Novo Nordisk INC | $44.61 | 2025 | Wegovy |
| Opko Pharmaceuticals, LLC | $41.54 | 2021-2023 | Rayaldee |
| Lilly USA, LLC | $39.13 | 2025 | Jardiance, Zepbound, Mounjaro |
| Fresenius USA Marketing, INC. | $35.06 | 2024-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $29.36 | 2025 | |
| Scpharmaceuticals INC. | $23.64 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $20.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaideep Hingorani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.